

CONTACTS

Robert White
President and Chief Executive Officer
TYRX, Inc.
732.246.8676
info@TYRX.com

TYRX Completes Study Site Enrollment in *CITADEL* & *CENTURION* Clinical Studies utilizing AIGISRx® Antibacterial Envelope during ICD/CRT Replacements

Monmouth Junction, NJ (October 28, 2010) – TYRX, Inc., a leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections (SSIs) associated with cardiac implantable electronic devices (CIEDs), announced today that it has completed the site enrollment phase of its 50-site *CITADEL* & *CENTURION* studies to evaluate the company's AIGISRx Antibacterial Envelope.

CITADEL & *CENTURION* are both large, prospective, multicenter clinical studies, which together, will enroll 4300 subjects at 50 clinical study sites across the U.S. Patients enrolled in these studies have a pacemaker, implantable cardioverter-defibrillator (ICD) or a cardiac resynchronization therapy (CRT) device that will be replaced with an ICD or CRT device accompanied by AIGISRx.

- In the *CITADEL* study, prospectively enrolled patients receiving AIGISRx will be compared to published controls who have undergone pacemaker, ICD or CRT device replacement with an ICD without AIGISRx.
- In the *CENTURION* study, prospectively enrolled patients will be compared to 2000 case-matched controls that have undergone pacemaker, ICD or CRT device replacement with a CRT without AIGISRx.

The primary endpoints for both studies will be 1) major ICD/CRT device-related infections and 2) ICD/CRT device-related mechanical complications. Patients will be followed for 12 months, with pre-defined interim analyses at 3 and 6 months.

The AIGISRx Envelope is an antibacterial mesh envelope designed to deliver antimicrobial agents which help provide protection against infections associated with implanted pacemakers and ICDs/CRTs. AIGISRx also securely holds a pacemaker or ICD/CRT in order to create a stable environment when implanted in the body.

“Published data shows us that the risk of CIED infection is higher for ICDs/CRTs in comparison to pacemakers. Additionally, replacement procedures carry more infection risk compared to initial implants. The *CITADEL* & *CENTURION* studies will provide vital information on the clinical performance of AIGISRx in these particularly high risk groups for CIED infection”, stated Scott Burkett, M.D., F.A.C.P., F.A.C.C., Burkett Heart Clinic, Monroe, Louisiana.

TYRX Chief Medical Officer, Daniel Lerner, M.D., commented that, “The rate of CIED infections is increasing faster than the rate of CIED implantations, which indicates a need for more effective antibiotic prophylaxis.”

CITADEL & *CENTURION* are registered in the ClinicalTrials.gov registry of federally and privately supported clinical trials conducted in the U.S. and around the world (www.ClinicalTrials.gov)

About TYRX, Inc.

TYRX, Inc. commercializes innovative, implantable combination drug/device products focused on infection control, including the AIGISRx® Antibacterial Envelope and AIGISRx® Flat Sheet products. AIGISRx products contain antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in cardiac implantable electronic device (CIED)-related endocarditis, including “superbugs” or MRSA*.

Following commercial release in 2008, the AIGISRx Envelope has been implanted in over 13,000 patients nationwide. The company estimates that approximately 2% of all U.S. CIED patients in 2010 will receive an AIGISRx product during their procedure.

TYRX, Inc. is an ISO 13485:2003 certified medical device manufacturer and its products utilize technology licensed exclusively from Rutgers, Baylor College of Medicine, and The University of Texas M. D. Anderson Cancer Center.

For more information, please visit <http://www.tyrx.com>.

* Based upon preclinical *in vitro* and *in vivo* data. Data on file at TYRX and published in *PACE* 2009; 32(7) 898-907.

###